Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug
Toronto, Ontario – September 12, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated increased efficacy with its latest, patented, licensed, anti-cancer drug, TLD-1633, when compared to its lead anti-cancer drug, TLD-1433.
The latest PDC, known as TLD-1633, has recently been shown to be approximately 15% more effective than TLD-1433 in the destruction of a human Glioblastoma Multiforme (“GBM”) cell line (U87), a deadly form of brain cancer.
In preclinical research, TLD-1633 has also demonstrated a lower dark toxicity, supporting an even higher safety profile than TLD-1433.
Pavel Kaspler, Ph.D., a research scientist at Theralase stated that, “Research on Theralase’s latest licensed anti-cancer drug, TLD-1633, is showing even stronger data preclinically than Theralase’s top performing anti-cancer drug TLD-1433. I look forward to expanding my research to assess the performance of TLD-1633 in various cancer lines, with and without the use of transferrin, as a transport system.”
Sherri McFarland, Ph.D., Professor, Department of Chemistry and Biochemistry, The University of North Carolina at Greensboro stated that, “TLD-1633 is a natural progression of the research work completed by our research labs in the development of TLD-1433. TLD-1633 has shown even stronger safety and efficacy in our labs than TLD-1433, and I am delighted to work with Theralase to optimize and expand their licenced PDC program, as we embark on additional cancer indications.”
Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer of Theralase stated that, “I am delighted that TLD-1633 has been added to our growing list of compounds, identified by Dr. McFarland’s research program, in conjunction with our own, as potent anti-cancer agents. TLD-1433 was originally chosen as the lead anti-cancer PDC in our fight against Non-Muscle Invasive Bladder Cancer (“NMIBC”), because of its strong characteristics, but it seems an even more potent PDC, TLD-1633, may be better suited to be utilized for other cancers of the body, such as GBM, especially when combined with transferrin. This is truly ground-breaking research that myself and the entire Theralase research team are delighted to be involved with.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase continues to expand our preclinical research and development, both in bringing new PDCs on-line and investigating new clinical applications, that we hope to translate into new clinical programs, in the not too distant future, via Phase Ib clinical studies.”
